German regulatory agency approves Rizaport to treat acute migraines
Rizaport, 5 mg and 10 mg, is an oral thin film formulation of rizatriptan benzoate. It is being developed by RedHill Biopharma and IntelGenx. It is the first
VERTANICAL has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for VER-01, its investigational non-opioid treatment for chronic low back pain.